Mark Klang

2.3k total citations · 1 hit paper
18 papers, 1.0k citations indexed

About

Mark Klang is a scholar working on Nutrition and Dietetics, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Mark Klang has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Nutrition and Dietetics, 5 papers in Pediatrics, Perinatology and Child Health and 3 papers in Molecular Biology. Recurrent topics in Mark Klang's work include Clinical Nutrition and Gastroenterology (8 papers), Pharmaceutical studies and practices (4 papers) and Child Nutrition and Feeding Issues (3 papers). Mark Klang is often cited by papers focused on Clinical Nutrition and Gastroenterology (8 papers), Pharmaceutical studies and practices (4 papers) and Child Nutrition and Feeding Issues (3 papers). Mark Klang collaborates with scholars based in United States and United Kingdom. Mark Klang's co-authors include Eddie Rosa, Victoria M. Richon, William P. Tong, Paul A. Marks, Lawrence B. Schwartz, Tracy Curley, Marija Drobnjak, Howard I. Scher, Richard A. Rifkind and Owen A. O’Connor and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Parenteral and Enteral Nutrition and JCI Insight.

In The Last Decade

Mark Klang

14 papers receiving 982 citations

Hit Papers

Phase I clinical trial of histone deacetylase inhibitor: ... 2003 2026 2010 2018 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
    2003 525 citations Wm. Kevin Kelly, Victoria M. Richon et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Klang United States 10 506 312 194 148 136 18 1.0k
Mathias Haarhaus Sweden 20 233 0.5× 130 0.4× 217 1.1× 69 0.5× 101 0.7× 54 1.2k
Carmen S. Amuchastegui Italy 9 177 0.3× 60 0.2× 57 0.3× 107 0.7× 149 1.1× 9 1.2k
Antje Fürstenberg United Kingdom 6 149 0.3× 79 0.3× 93 0.5× 202 1.4× 170 1.3× 6 735
K.C.H. Fearon United Kingdom 15 293 0.6× 273 0.9× 443 2.3× 1.1k 7.1× 113 0.8× 28 1.8k
E. Aulbert Germany 9 89 0.2× 266 0.9× 174 0.9× 443 3.0× 155 1.1× 23 826
Karla Sánchez-Lara Mexico 14 96 0.2× 218 0.7× 356 1.8× 562 3.8× 261 1.9× 30 1.1k
Atsushi Uchiyama Japan 18 338 0.7× 135 0.4× 38 0.2× 223 1.5× 456 3.4× 65 1.2k
Mariann I. Lassenius Finland 14 282 0.6× 45 0.1× 44 0.2× 253 1.7× 80 0.6× 40 870
D H Van Thiel United States 18 107 0.2× 82 0.3× 88 0.5× 100 0.7× 67 0.5× 44 950
Michael Glatzel Germany 17 101 0.2× 178 0.6× 201 1.0× 142 1.0× 208 1.5× 26 859

Countries citing papers authored by Mark Klang

Since Specialization
Citations

This map shows the geographic impact of Mark Klang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Klang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Klang more than expected).

Fields of papers citing papers by Mark Klang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Klang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Klang. The network helps show where Mark Klang may publish in the future.

Co-authorship network of co-authors of Mark Klang

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Klang. A scholar is included among the top collaborators of Mark Klang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Klang. Mark Klang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Park, Hyeung Ju, Jinyeon Shin, Mark Klang, et al.. (2025). TGF-β–mediated epithelial-mesenchymal transition of keratinocytes promotes fibrosis in secondary lymphedema. JCI Insight. 10(17).
2.
Chapman, Paul B., Mark Klang, Michael A. Postow, et al.. (2023). Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib. Cancer Research Communications. 3(12). 2447–2454. 4 indexed citations
3.
Chapman, Paul B., Mark Klang, Michael A. Postow, et al.. (2023). Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.. Journal of Clinical Oncology. 41(16_suppl). 9536–9536.
4.
Klang, Mark. (2023). Developing guidance for feeding tube administration of oral medications. Journal of Parenteral and Enteral Nutrition. 47(4). 519–540. 10 indexed citations
5.
Baik, Jung Eun, Hyeung Ju Park, Raghu P. Kataru, et al.. (2022). TGF‐β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation. Clinical and Translational Medicine. 12(6). e758–e758. 43 indexed citations
6.
Boullata, Joseph I., Arlene A. Escuro, Lauren Hudson, et al.. (2016). ASPEN Safe Practices for Enteral Nutrition Therapy. Journal of Parenteral and Enteral Nutrition. 41(1). 15–103. 284 indexed citations
7.
8.
Klang, Mark. (2015). PFAT5 and the Evolution of Lipid Admixture Stability. Journal of Parenteral and Enteral Nutrition. 39(1S). 67S–71S. 21 indexed citations
9.
Klang, Mark. (2015). Recommendations for compounding medications for feeding tube administration.. PubMed. 14(4). 276–82. 3 indexed citations
10.
Krug, Lee M., Marjorie G. Zauderer, Erin McGee, et al.. (2015). Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.. Journal of Clinical Oncology. 33(15_suppl). 7559–7559. 6 indexed citations
11.
Klang, Mark, et al.. (2013). Osmolality, pH, and Compatibility of Selected Oral Liquid Medications With an Enteral Nutrition Product. Journal of Parenteral and Enteral Nutrition. 37(5). 689–694. 45 indexed citations
12.
Klang, Mark, et al.. (2010). Warfarin Bioavailability With Feeding Tubes and Enteral Formula. Journal of Parenteral and Enteral Nutrition. 34(3). 300–304. 12 indexed citations
13.
Kelly, Wm. Kevin, Victoria M. Richon, Owen A. O’Connor, et al.. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.. PubMed. 9(10 Pt 1). 3578–88. 525 indexed citations breakdown →
14.
Klang, Mark. (2003). Human Rights and the Internet. International Journal of Law and Information Technology. 11(1). 106–108.
15.
Malkin, Mark G., Jeffrey S. Groeger, Mark Heaney, et al.. (2002). Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices. Journal of Clinical Oncology. 20(7). 1918–1922. 18 indexed citations
16.
Schiano, Thomas D., et al.. (1996). Thiamine status in patients receiving long-term home parenteral nutrition.. PubMed. 91(12). 2555–9. 13 indexed citations
17.
Klang, Mark. (1996). Medicating tube-fed patients.. PubMed. 26(1). 18–18. 2 indexed citations
18.
Hornsby-Lewis, L., Moshe Shike, Patricia Brown, et al.. (1994). L‐Glutamine Supplementation in Home Total Parenteral Nutrition Patients: Stability, Safety, and Effects on Intestinal Absorption. Journal of Parenteral and Enteral Nutrition. 18(3). 268–273. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mathias Haarhaus Breakdown of academic impact, for papers by Carmen S. Amuchastegui Breakdown of academic impact, for papers by Antje Fürstenberg Breakdown of academic impact, for papers by K.C.H. Fearon Breakdown of academic impact, for papers by E. Aulbert Breakdown of academic impact, for papers by Karla Sánchez-Lara Breakdown of academic impact, for papers by Atsushi Uchiyama Breakdown of academic impact, for papers by Mariann I. Lassenius Breakdown of academic impact, for papers by D H Van Thiel Breakdown of academic impact, for papers by Michael Glatzel
Rankless by CCL
2026